Updating results

1901 results

Sort: Relevance | Date

Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

Summary of the evidence on aripiprazole prolonged-release suspension for injection for schizophrenia to inform local NHS planning and decision-making

Evidence summary Published March 2014

Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)

Summary of the evidence on tiotropium/olodaterol (Spiolto Respimat) for treating chronic obstructive pulmonary disease (COPD)..

Evidence summary Published May 2016

External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment (ESNM66)

Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

Evidence summary Published December 2015

Type 2 diabetes: dulaglutide (ESNM59)

Summary of the evidence on dulaglutide for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published June 2015

Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)

Summary of the evidence on beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) for treating asthma in adults..

Evidence summary Published January 2015

Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

Summary of the evidence on sucroferric oxyhydroxide for treating hyperphosphataemia in adults with chronic kidney disease (CKD) on dialysis..

Evidence summary Published January 2015

Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)

Summary of the evidence on umeclidinium inhaler (Incruse) for chronic obstructive pulmonary disease to inform local NHS planning and decision-making

Evidence summary Published January 2015

Schizophrenia: lurasidone (ESNM48)

Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

Evidence summary Published September 2014

Type 2 diabetes: insulin degludec (ESNM25)

Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Parkinson's disease with motor fluctuations: safinamide (ES6)

Summary of the evidence on safinamide for treating Parkinson’s disease with motor fluctuations to inform local NHS planning and decision-making

Evidence summary Published February 2017

Refractory extrapulmonary sarcoidosis: infliximab (ES4)

Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published January 2017

Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

Summary of the evidence on telavancin (Vibativ) for hospital-acquired pneumonia caused by MRSA to inform local NHS planning and decision-making

Evidence summary Published July 2014

Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

Summary of the evidence on zonisamide as adjunctive therapy for partial seizures in children and young people (aged 6–17 years) with epilepsy..

Evidence summary Published March 2014

Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

Summary of the evidence on triptorelin (Decapeptyl SR) for treating prostate cancer to inform local NHS planning and decision-making

Evidence summary Published January 2014

Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

Summary of the evidence on opicapone for reducing end-of-dose motor fluctuations in Parkinson’s disease to inform local NHS planning and decision-making

Evidence summary Published March 2017

Clostridium difficile infection: fidaxomicin (ESNM1)

Summary of the evidence on fidaxomicin for treating Clostridium difficile (C. diff/C. difficile) infection to inform local NHS planning and decision-making

Evidence summary Published July 2012

Gouty arthritis: canakinumab (ESNM23)

Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

Summary of the evidence on the indacaterol/glycopyrronium (Ultibro Breezhaler) for relieving the symptoms of chronic obstructive pulmonary disease (COPD)..

Evidence summary Published February 2014 Last updated March 2014

Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

Evidence summary Published September 2014

Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

Summary of the evidence on beclometasone/formoterol (Fostair) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published September 2014

The Space GlucoseControl system for managing blood‑glucose in critically ill patients in intensive care (MIB17)

Advice on the use of the Space GlucoseControl system for managing blood-glucose in critically ill patients in intensive care to aid local decision-making

Medtech innovation briefing Published December 2014

The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (MIB18)

Advice on the use of AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (CPR) to aid local decision-making

Medtech innovation briefing Published February 2015

Shiley Endotracheal Tube with TaperGuard Cuff for intensive care patients at risk of ventilator‑associated pneumonia (MIB22)

Advice on the use of Shiley Endotracheal Tube with TaperGuard Cuff for patients at risk of ventilator-associated pneumonia to aid local decision-making

Medtech innovation briefing Published March 2015

The PediGuard for placing pedicle screws in spinal surgery (MIB26)

Advice on the use of the PediGuard for placing pedicle screws in spinal surgery to aid local decision-making

Medtech innovation briefing Published March 2015

Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)

Advice on the use of the Xpert GBS test for the intrapartum detection of group B streptococcus (GBS) colonisation in pregnant women...

Medtech innovation briefing Published April 2015

Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)

Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making

Evidence summary Published November 2016

Needle-free arterial non-injectable connector (MIB85)

Advice on the use of needle-free arterial non-injectable connector through which blood samples can be collected to aid local decision-making

Medtech innovation briefing Published October 2016

Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

Evidence summary Published March 2017

Hyperhidrosis: oxybutynin (ES10)

Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published March 2017

The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)

Advice on the use of the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies to aid local decision-making

Medtech innovation briefing Published March 2015

S-Cath System for suprapubic catheterisation (MIB68)

Advice on the use of the S-Cath System for suprapubic catheterisation to aid local decision-making

Medtech innovation briefing Published June 2016

Long-acting reversible contraception: subcutaneous depot medroxyprogesterone acetate (DMPA‑SC) (ESNM31)

Summary of the evidence on subcutaneous depot medroxyprogesterone acetate (DMPA-SC) for long-acting reversible contraception..

Evidence summary Published January 2014

The V.A.C. Veraflo Therapy system for infected wounds (MIB189)

Advice on the use of the V.A.C. Veraflo Therapy system for infected wounds to aid local decision making

Medtech innovation briefing Published September 2019

InterDry for intertrigo (MIB192)

Advice on the use of InterDry for intertrigo (inflammatory skin rash) to aid local decision making

Medtech innovation briefing Published September 2019

UroShield for preventing catheter-associated urinary tract infections (MIB191)

Advice on the use of UroShield for preventing catheter-associated urinary tract infections (CAUTI) to aid local decision making

Medtech innovation briefing Published September 2019

SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea (MIB190)

Advice on the use of SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea to aid local decision making

Medtech innovation briefing Published September 2019

Alpha-Stim AID for anxiety (MIB193)

Advice on the use of Alpha-Stim AID for anxiety to aid local decision making

Medtech innovation briefing Published September 2019

The percentage of patients aged 80 years or over with peripheral arterial disease in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less.

The percentage of patients aged 80 years or over with peripheral arterial disease in whom the last blood pressure reading (measured in the preceding...

QOF indicator Published August 2019

The percentage of patients aged 80 years or over with coronary heart disease in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less.

The percentage of patients aged 80 years or over with coronary heart disease in whom the last blood pressure reading (measured in the preceding 12...

QOF indicator Published August 2019

The percentage of patients aged 80 years and over with a history of stroke or TIA in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less

The percentage of patients aged 80 years and over with a history of stroke or TIA in whom the last blood pressure reading (measured in the preceding...

QOF indicator Published August 2019

The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or dementia who have been screened for hazardous drinking using the FAST or AUDIT-C tool in the preceding 2 years.

The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or...

QOF indicator Published August 2019

The percentage of patients with heart failure on the register, who had a review in the preceding 12 months, including an assessment of functional capacity (using the New York Heart Association classification) and a review of medication

The percentage of patients with heart failure on the register, who had a review in the preceding 12 months, including an assessment of functional...

QOF indicator Published July 2019

The percentage of patients with a new diagnosis of hypertension in the preceding 12 months with a FAST score of ≥3 or AUDIT-C score of ≥5 who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded

The percentage of patients with a new diagnosis of hypertension in the preceding 12 months with a FAST score of ≥3 or AUDIT-C score of ≥5 who have...

QOF indicator Published August 2019

The percentage of patients with a new diagnosis of hypertension in the preceding 12 months who have been screened for hazardous drinking using the FAST or AUDIT-C tool in the 3 months before or after the date of entry on the hypertension register

The percentage of patients with a new diagnosis of hypertension in the preceding 12 months who have been screened for hazardous drinking using the...

QOF indicator Published August 2019

The percentage of patients with a new diagnosis of depression or anxiety in the preceding 12 months who have been screened for hazardous drinking using the FAST or AUDIT-C tool in the 3 months before or after their diagnosis being recorded

The percentage of patients with a new diagnosis of depression or anxiety in the preceding 12 months who have been screened for hazardous drinking...

QOF indicator Published August 2019